302
Participants
Start Date
February 10, 2017
Primary Completion Date
February 7, 2019
Study Completion Date
February 7, 2019
BIIB074
Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Blagoevgrad
Research Site, Leuven
Research Site, Sofia
Research Site, Veliko Tarnovo
Research Site, Rousse
Research Site, Klagenfurt
Research Site, Prague
Research Site 1, Belgrade
Research Site 2, Belgrade
Research Site, Prague
Research Site, Prague
Research Site, Granada
Research Site, Belgrade
Research Site, Beroun
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Prachatice
Research Site, Litoměřice
Research Site, Tartu
Research Site, Choceň
Research Site, Litomyšl
Research Site, Ostrava
Research Site, Paris
Research Site, Zlín
Research Site, Prague
Research Site, Craiova
Research Site, Cluj-Napoca
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Rome
Research Site, Liepāja
Research Site, Riga
Research Site, Riga
Research Site, Bucharest
Research Site, Banská Bystrica
Research Site, Dubnica nad Váhom
Research Site, Krompachy
Research Site, Pruské
Research Site, Spišská Nová Ves
Research Site, Barcelona
Research Site, Edinburgh
Research Site, Liverpool
Research Site, London
Research Site, London
Lead Sponsor
Biogen
INDUSTRY